Category Biology/Biotechnology

Exhaustion creeps in. Appetite vanishes. Hair thins. The person in the mirror looks gaunt. It’s the paradox of cancer treatment: The same drugs meant to save a life can also wear the body down. Nick Housley, assistant professor in Georgia Tech’s School of Biological Sciences, wants to change that. He studies where cancer drugs go once they’re inside the body, including places they were never intended to reach. Some of the medicine finds the tumor. The rest interacts with healthy tissue.

This approach has saved mill...

Northwestern Medicine scientists led by Joseph Bass, MD, Ph.D., the Charles F. Kettering Professor of Endocrinology and Metabolism and director of the Center for Diabetes and Metabolism, have discovered how disruptions in the circadian rhythm impair metabolic function in fat cells, providing new insights into the molecular mechanisms that cause obesity and metabolic disease, according to a recent study published in Nature Metabolism.

“It’s not simply the accrual of excess fat that leads to disease...

Researchers at Baylor College of Medicine have discovered a potential new strategy to fight back against Alzheimer’s and Parkinson’s diseases, conditions that are linked to the toxic accumulation of Tau and alpha synuclein protein clumps in the brain. The team reports in Nature Communications that tubulin, the building block of microtubules, the cell’s internal ‘railway tracks,” can stop Tau and alpha synuclein from forming toxic clumps and instead steer them into their normal, healthy roles.

“Tau and alpha synuclein are well known for their roles in neurodegenerative diseases like Alzheimer’s and Parkinson’s...

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes and obesity is independently associated with a significantly increased five-year risk for osteoporosis, gout, and osteomalacia compared with nonuse, according to a study presented at the annual meeting of the American Academy of Orthopaedic Surgeons, held from March 2 to 6 in New Orleans.

Muaaz Wajahath, from the Michigan State University College of Human Medicine in East Lansing, and colleagues evaluated the five-year risk for osteoporosis, gout, and osteomalacia in adults with both type 2 diabetes and obesity treated with GLP-1 RAs (semaglutide, liraglutide, dulaglutide, or exenatide) compared with matched controls (73,483 per group).

The researchers found that at five years, patients expo...